Natixis contributes to rolling back malaria
Engaged for 10 years in the fight against malaria, Natixis provides its active support to prevention and treatment programs in endemic areas and to the research conducted on the disease. Through this support, it contributes to rolling back the disease in the world.
Remarkable progress in the fight against malaria
The latest World Malaria Report by the World Health Organization (WHO) shows that the number of malaria cases is continuing to decline significantly. The mortality rate due to malaria has dropped by 47% between 2000 and 2013 on a global basis, and by 54% in the African region.
These significant advances were achieved through the use of insecticide-treated mosquito nets, the populations' access to diagnostic testing and to artemisinin-based combination therapies (ACTs).
Natixis acts against malaria
Since 2005, Natixis has been supporting the Plan International France NGO in the field to implement prevention programs in Cameroon, Burkina Faso and Togo. In 2014, Natixis has continued to support the fight against malaria led by Plan France with 18,000 children and 4,000 pregnant women in 52 villages of Togo.
Meanwhile, Natixis has been supporting since 2005 the Institut Pasteur research programs devoted in particular to the study on the resistance of parasites to antimalarial treatment. Natixis sponsorship contributed to the identification of a molecular marker for detecting malaria parasites with resistance to artemisinin derivatives and the realization of a global mapping of this resistance in endemic areas. These data will provide WHO and local health authorities the information necessary to change treatment regimens accordingly.
The continuation of these achievements would allow to hope for a quasi-elimination of the malaria, in line with Millennium development goals.